Characterization of C3 receptors on cultured rat glomerular endothelial cells  by Alexander, Jessy J. et al.
Kidney International, Vol. 51(1997), pp. 1124—1132
Characterization of C3 receptors on cultured rat glomerular
endothelial cells
JESSY J. ALEXANDER, CHUN HE, STEPHEN ADLER, V. MICHAEL HOLERS, and RICHARD J. Quio
Department of Medicine, Section of Nephrology, The University of Chicago, Chicago, Illinois; Department of Medicine, Division of Nephrology, New York
Medical College, Valhalla, New York; and Department of Medicine, Division of Rheumatology, University of Colorado Health Sciences Center, Denver,
Colorado, USA
Characterization of C3 receptors on cultured rat glomerular endothe-
hal cells. In this study we characterized C3 receptors on cultured rat
glomerular endothehial cells (GEnC), using immunochemical and molec-
ular techniques. GEnC membrane proteins were immunoprecipitated with
a polyclonal antibody directed towards mouse complement receptor 2
(CR2). This anti-MCR2 immunoprecipitated GEnC proteins of 120 and
150 kDa. By immunohistochemistry, anti-MCR2 stained GEnC in rat
glomeruli in vivo. Given the presence of CR2-like proteins on GEnC,
subsequent studies were done to determine whether GEnC had C3-
binding proteins. GEnC proteins of 80, 200, and 300 kDa specifically
bound to columns of rat C3d-Sepharose and C3b-Sepharose, illustrating
that these proteins were binding to the C3d portion of C3. The 80, 200,
and 300 kDa C3d-binding proteins were distinct from the 120 and 150 kDa
anti-MCR2 reactive proteins, as shown by immunoabsorption studies.
Next, a specific eDNA probe for rat CR2 was generated by RT-PCR.
Oligonucleotides were chosen from highly conserved regions in mouse and
human CR2 spanning 224 bases, with the rationale that these would also
be conserved in the rat. A 224 bp PCR product was generated from both
rat GEnC and rat kidney eDNA, illustrating the presence of CR2 mRNA
in these tissues. By Northern analysis, the CR2 PCR product hybridized to
mRNA of 2 and 5 kb from GEnC. The 5 kb transcript was also identified
in rat kidney mRNA. Therefore, proteins immunologically related to
mouse CR2 are present in GEnC in vitro and in vivo. C3d-binding proteins
of 80, 200, and 300 kDa are also present on rat GEnC, yet these appear to
be immunologically distinct from the proteins identified by anti-MCR2.
Whether the GEnC CR2 mRNA transcripts of 2 and 5 kb are translated
into the 80 and 200 kDa C3d-binding proteins or the 120 and 150 kDa
mouse CR2-like proteins remains to be defined.
In humans, complement receptor 1 (CR1) and CR2 are mem-
bers of the regulators of complement activation gene cluster, and
have primary specificity for C3b and C3d, respectively [1, 21.
Proteins in this family share a common 60 amino acid short
consensus repeat (SCR), containing a framework of four cysteine
residues, along with other conserved amino acids [2, 3]. This
common ancestral precursor appears to have been duplicated
many times, and is present in other complement proteins (Cir,
Cl s, C2, and factor B) as well as other non-complement proteins
(such as, interleukin-2 receptor, factor XIII subunit) [2]. Of the
nonhuman species, complement receptors in the mouse have been
the most completely elucidated. Mouse CR1 and CR2 are en-
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coded by alternatively spliced Cr2 gene transcripts [4—7]. Conse-
quently, both proteins share 15 SCRs, and both are recognized by
monoclonal and polyclonal anti-CR2 antibodies [8, 91.
Human CR1 has a fairly wide distribution and is present on B-
and T-lymphocytes, monocytes, macrophages, neutrophils, eryth-
rocytes, and glomerular epithelial cells. In contrast, human CR2
has a more restricted distribution, being located on B-lympho-
cytes, a subset of T-lymphocytes, epithehial cells, and follicular
dendritic cells [10—12]. Similar to human CR2, both mouse CR1
and CR2 have a limited distribution, and are expressed solely on
B-lymphocytes and follicular dendritic cells [13]. In neither spe-
cies have CR1 or CR2 been identified on endothelial cells.
In the mouse and rat, proteins that bind C3b are present on
unstimulated neutrophils and platelets, yet they are not CR1 or
CR2 [8, 14]. In recent studies, we have identified two C3b-binding
proteins of 80 and 200 kDa on rat platelets and neutrophils,
named C3bR-80 and C3bR-200 [14]. These were not immunopre-
cipitated by antibodies to human or mouse CR1/CR2. Therefore,
these proteins most likely serve as the rat immune adherence
receptors. From the available information, C3bR-80 and C3bR-
200 appear to be distinct from CR1 and CR2. Still, since the
eDNA of these proteins remain uncloned, this remains specula-
tive.
In the course of our studies on complement regulators and
receptors in rat glomerular cells [15, 16], we noted that polyclonal
anti-mouse CR2 antibodies (anti-MCR2) reacted with cultured
rat glomerular endothehial cells (GEnC). We were therefore
interested in further characterizing C3d receptors on GEnC, using
immunochemical and molecular techniques.
Methods
Antibodies
An Escherichia coli trpE-mouse CR2 fusion protein, containing
SCRs 1-10, was used to make rabbit anti-MCR2 antibodies as
described previously [7]. Anti-MCR2 IgG was isolated by protein
G-Sepharose affinity chromatography (Pharmacia, Piscataway,
NJ, USA). Anti-human C3d was obtained from Dako (Carpinte-
na, CA, USA), and cross-reacts with rat C3d [17J.
Affinity columns
Rat C3 was isolated as described previously [18]. Briefly, rat C3
was purified by a 5 to 11% polyethylene glycol precipitation
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followed by Mono 0 anion exchange chromatography (Pharma-
cia). The resulting preparation was pure by SDS-PAGE. C3d was
generated by trypsinization (10% wt/wt, 3 hr, 37°C) and bound via
its free sulfhydryl group to thiopropyl-Sepharose (Pharmacia).
The supernatant that was not bound to thiopropyl-Sepharose was
collected. From an aliquot of C3d-Sepharose, bound C3d was
released from the beads by incubation in 1 mtvi 2-mercaptoetha-
no!. In this C3d-Sepharose column, the C3 a chain was present
only as the 30 kDa C3d fragment as shown by Western blotting
[181 with anti-C3d (Fig. 1, Lane 2, large arrow). Not bound to
Sepharose were C3c fragments (Lane 1), as well as small amounts
of intact a and a' chains (small arrows). Rat C3b-Sepharose was
prepared as described previously [181.
As a control column, 42 mg BSA (Sigma Chemical Co., St.
Louis, MO, USA) was bound to 1.5 gm CNBr-Sepharose (Phar-
macia) according to the manufacturer's instructions.
GEnC culture
Rat GEnC were cultured as described elsewhere [19]. Cells
were grown on culture dishes coated with fibronectin (Collabora-
tive Research, Bedford, MA, USA) in RPMI-1640 medium (Life
Technologies, Gaithersburg, MD, USA) with 10% fetal bovine
serum and 10% Nu-Serum (Collaborative Research). GEnC were
characterized by their morphology, the ability to take up di-acetyl
LDL, and the possession of angiotensin converting enzyme activ-
ity [19]. Cells were used between passages 16 and 20.
Immunohistochemistiy
Normal rat kidneys were snap frozen in isopentane on dry ice,
Five micrometer sections were cut and fixed in 4% paraformal-
dehyde. Endogenous peroxidase activity was quenched with 0.3%
H202 in methanol and sections were blocked in 10% normal goat
serum. Tissue was then sequentially incubated in anti-MCR2 IgG
or normal rabbit IgG as a control (0.1 mg/mI), biotinylated goat
anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA),
ABC development reagent (Vector), and diaminobenzidine. Sec-
tions were then counterstained with alcian blue and methyl green,
and dehydrated in graded ethanols.
Immunoprecipitations
GEnC in culture dishes were surface radiolabeled with 125!
using lactoperoxidase and H202 as previously described [16].
Following labeling, cells were incubated in phosphate buffered
saline (PBS) containing 1 mivi EDTA for 20 minutes at room
temperature with periodic agitation, and cells not detached after
this time were removed from the substratum with a rubber
policeman. Cells were washed with PBS, and then solubilized for
15 minutes on ice in 1 ml PBS, pH 7.2, containing 10 mM EDTA,
10 mM iodoacetamide (Sigma), 5 mivi diisopropylfluorophosphate
(Sigma), 1% NP-40. Nuclei and cytoplasmic debris were pelleted
at 14,000 X g. Unincorporated Na1251 was removed by Sephadex
G-25 chromatography (Pharmacia). By this technique, 4 to 6 X










Fig. 1. Western blot analysis of C3d-Sepharose with anti-C3d. C3 fragments
remaining unbound (lane 1) and bound (lane 2) to C3d-Sepharose were
analyzed by reducing SDS-PAGE followed by immunoblotting with anti-
human C3d. 1 2
Fig. 2. Immunoprecipitation of GEnC membrane proteins with anti-MCR2.
Surface radiolabeled GEnC were immunoprecipitated with anti-MCR2
(lane 2) or nonimmune IgG (lane 1), separated by reducing SDS-PAGE,





































Fig. 3. Immunoperoxidase staining for CR2 in normal rat kidney. Sections were incubated with anti-MCR2 IgG (A, X400; C, >< 1000) or with nonimmune
IgG (B, x400). Publication of this figure in color was made possible by a grant from Hoechst Marion Roussel, Kansas City, MO, USA.
106 trichioroacetic acid precipitable cpm were obtained per
culture dish.
After preclearing of antigens with normal rabbit serum and
protein G-Sepharose, antigens were immunoprecipitated with 200
tg rabbit anti-MCR2 IgG or 200 xg nonimmune rabbit IgG as a
control, followed by addition of 50 l protein G-Sepharose (50%
vol/vol). After thorough washing with 0.6 M NaCl, 0.05 M Tris-
HCI, pH 7.5, 0.2% NP-40, immunoprecipitated proteins were
subjected to SDS-PAGE and autoradiography.
Affinity chromatography
For C3d affinity chromatography, solubilized '251-labeled
GEnC membrane proteins were diluted with 1-120 and PBS to
final NaCl and NP-40 concentrations of 0.05 M and 0.1%, respec-
tively. Low ionic strength is necessary because of the low affinity
interactions between complement receptors and C3 fragments
[18, 20]. These preparations were applied to BSA-Sepharose and
C3d-Sepharose columns in series. The BSA-Sepharose column
was used to exclude nonspecifically bound proteins from the
C3d-Sepharose column. Once samples had passed through the
BSA-Sepharose column, it was disconnected. Columns were
washed with 50 column volumes of 0.05 M NaCl, 0.01 M Na
phosphate, pH 7.2, 0.1% NP-40. Specifically bound material was
eluted with 0.5 M NaCI, 0.02 M Na phosphate, pH 7.2, 0.1% NP-40,
and analyzed by SDS-PAGE and autoradiography. C3b affinity
chromatography was performed similarly.
In a group of experiments designed to evaluate whether pro-
teins were binding specifically to C3d-Sepharose, '251-labeled
GEnC membrane proteins were diluted to final NaC1 and NP-40
concentrations of 0.05 M and 0.1%, respectively. The sample was
divided in half and applied to identically sized columns of
BSA-Sepharose or C3d-Sepharose. The columns were washed
and specifically bound proteins eluted as before. Equivalent
volumes of eluted material were compared by SDS-PAGE and
autoradiography.
To immunoabsorb GEnC proteins reactive with anti-MCR2
prior to C3d affinity chromatography, 25I-labe1ed membrane
proteins were first incubated with 1.0 mg anti-MCR2 or normal
rabbit IgG as a control, and then incubated with 0.7 ml protein
G-Sepharose (50% vol/vol). The supernatant was then diluted to
0.05 M NaCI and 0.1% NP-40, and subjected to C3d affinity
chromatography as described above. Proteins immunoprecipi-
tated by anti-MCR2 or nonimmune IgG contained in the protein
G pellets were processed as detailed in the previous section.
Eiythrocyte rosetting assay
Sheep erythrocytes (E) bearing C3b (EC3b) were prepared as
described previously [21]. By this technique, C3 was treated with
trypsin to generate C3b, which also leads to the production of
smaller amounts of C3bi [181. The protocol described by Kasinath
et alto evaluate complement receptors in glomerular epithelial
cells was followed [22]. Briefly, confluent GEnC were washed
three times with Hank's balanced salt solution (HBSS), and then
incubated with EC3b. As a control, E not bearing C3b were used.
E or EC3b were added at 1 X 107/ml in HBSS and incubated with
GEnC for 60 minutes at 37°C with continuous shaking. Cells were
washed three times with HBSS, and the numbers of E or EC3b per
high powered field (x 200) were counted under an inverted phase
contrast microscope. Data were compared by unpaired t-testing.
Reverse transcription (RT) and the polymerase chain reaction
(PCR)
Total RNA from GEnC and normal rat kidney were isolated by
a single-step guanidinium isothiocyanate-phenol-chioroform ex-
traction (Tn-Reagent; MRC, Inc., Cincinnati, OH, USA).
Poly(A) RNA was purified by affinity chromatography on
oligo-dT cellulose columns (MRC). Mouse spleen poly(A) RNA
was obtained from Clontech (Palo Alto, CA, USA). Genomic
DNA from rat and mouse liver were isolated by treatment of
tissues with SDS and proteinase K, followed by phenol/chioro-
form/isoamyl alcohol extractions [23].
Highly conserved areas in the nucleotides that encode the
eleventh and twelfth SCRs of both human and murine CR2
(spanning 224 bases) were used to design oligonucleotide primers
for PCR. The sequences of the 5' sense primer was (5'-TGT-
CAAAATGCTGAGAATGGGAC-3'), and that of the 3' anti-
sense primer was (5'-CTCCAAGAGCCATGACCYVFAGAA-
3'), both of which correspond to the mouse sequence. cDNA was
produced from 1 xg poly (A) mRNA by RT using random
hexamers (SuperScript Preamplification System; GIBCO BRL).
Subsequent PCR was performed in tubes containing RT-gener-
ated eDNA or genomic DNA, 50 mi KCI, 20 m't Tris-HCI, 2.5
mM MgCl2, 100 xgJmI BSA, 100 jxM of each deoxynucleotide
triphosphate, 0.1 LM of each primer, and 2.5 U Taq polymerase.
Thirty cycles of a one minute denaturation at 94°C, one minute
annealing at 60°C, and one minute extension at 72°C were
performed. The products thus formed were electrophoresed
through a 1.5% agarose gel and stained with ethidium bromide.
The specific rat CR2 PCR product (Results) was purified by
preparative agarose gel electrophoresis and extracted from the gel
with a commercially obtained kit (MERMAID; Bio 101, La Jolla,
CA, USA).
Northern analyses
One microgram of poly(A) RNA from cultured GEnC or
normal rat kidney was electrophoresed through a denaturing
agarose gel. RNA was transferred by capillary action to a nylon
membrane and cross-linked to the membrane by ultraviolet
irradiation. The specific CR2 cDNA probe and a 13-actin cDNA
[241 were random primer labeled with [a-32P]dCTP. Hybridiza-
tion and washing were performed under high stringency as
described previously [24].
Results
Reactivity of anti-MCR2 with GEnC in vitro and in vivo
While studying complement receptors in cultured rat glomeru-
lar cells, we included anti-MCR2 in our immunoprecipitation
analyses. Surprisingly, anti-MCR2 specifically immunoprecipi-
tated GEnC proteins of 120 and 150 kDa as determined by
reducing SDS-PAGE (Fig. 2, lane 2). Under non-reducing condi-
tions, these two migrated slightly faster, at calculated molecular
weights of 115 and 145 kDa, respectively (not shown). The 150
kDa protein is consistent with the sizes of human and mouse CR2
[5,7].
By immunohistochemistry, anti-MCR2 clearly reacted with
intrinsic glomerular cells (Fig. 3). The cytoplasm of GEnC
appeared to be stained (Fig. 3C, arrows). Furthermore, in some







Fig. 4. C3d affinity chromatography of GEnC membrane proteins. Surface
radiolabeled GEnC were subjected to C3d affinity chromatography,
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Fig. 5. Immunoabsoiption of GEnC membrane proteins prior to C3d
affinity chromatography. Surface radiolabeled GEnC were immunoab-
sorbed with nonimmune IgG (lane 4) or anti-MCR2 IgG (lane 6) prior to
C3d affinity chromatography. Proteins immunoprecipitated in this exper-
iment by nonimmune IgG (lane 1) and anti-MCR2 (lane 2) were
electrophoresed on the same reducing SDS-polyacrylamide gel.
cells, staining over nuclei was evident (Fig. 3C, arrowheads).
There was also focal mesangial cell staining apparent (Fig. 3A,
white arrows). These data show that GEnC in vitro and in vivo
contain proteins reactive with anti-MCR2.
C3d affinity chromatography
Given the presence of CR2-like proteins on GEnC, we were
interested to determine whether these proteins bound C3d. By
C3d affinity chromatography, proteins of 80 and 200 kDa were
recovered from GEnC (as shown by reducing SDS-PAGE, Fig. 4,
arrows). These findings were reproducible in four separate exper-
iments. In addition, a C3d-binding protein with an approximate
molecular weight of 300 kDa was identified that had variable
intensity in different experiments (Fig. 4, open arrow). These
three C3d-binding proteins bound equivalently to C3b-Sepharose
(not shown), illustrating that these proteins were binding to the
C3d portion of C3b.
We performed further studies to characterize these C3d-bind-
ing proteins more completely. Although their molecular weights
suggested they were distinct from the 120 and 150 kDa proteins
immunoprecipitated by anti-MCR2, we conducted experiments to
confirm that these two groups of proteins were unrelated. Radio-
labeled GEnC proteins were first immunoabsorbed with anti-
1 2
Fig. 6. Comparison of GEnC membrane proteins bound to C3d-Sepharose
with those bound to BSA-Sepharose. Surface radiolabeled GEnC mem-
brane proteins were subjected to affinity chromatography on C3d-Sepha-
rose (lane 1) or BSA-Sepharose (lane 2). Proteins eluted with high salt
buffer from the columns were electrophoresed on a reducing SDS-
polyaciylamide gel followed by autoradiography. Both lanes were run on
the same gel, but have been spliced for this analysis.
MCR2 or normal rabbit IgG prior to C3d affinity chromatography.
As shown in Figure 5, proteins of 80, 200, and 300 kDa were
recovered by C3d affinity chromatography in GEnC proteins first
absorbed with nonimmune rabbit IgG (lane 4, arrows), compara-
ble to our previous results. Preabsorption with anti-MCR2 did not
affect the subsequent recovery of proteins from the C3d-Sepha-
rose column (lane 6). For purposes of comparison, proteins
immunoprecipitated by nonimmune IgG and anti-MCR2 in these
experiments are shown in lanes I and 2, respectively. In addition,
the fractions collected from the C3d-Sepharose columns following
washing but immediately before elution are shown in lanes 3
(nonimmune IgG preabsorption) and 5 (anti-MCR2 IgG preab-
sorption). These confirm that the identified C3d-binding proteins
were specifically eluted from the column with high salt buffer.
Therefore, the 80, 200, and 300 kDa C3d-binding proteins of
GEnC are immunologically distinct from those proteins identified
by anti-MCR2.
When the C3d-binding proteins were subjected to SDS-PAGE
under non-reducing conditions, they migrated at calculated mo-
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Fig. 7. RT-PCR analysis using CR2 oligonucleotide primers. A. Poly(A) RNA from GEnC (lane 1), rat kidney (lane 3), or mouse spleen (lane 4) were
subjected to RT-PCR using oligonucleotide primers chosen from conserved regions in human and mouse CR2 separated by 224 bases. In lane 2 is the
negative control that lacked RNA, but was otherwise treated identically. B. PCR was also performed on rat (lane 1) and mouse (lane 2) genomic DNA
using these CR2 primers.
are consistent with the presence of intrachain disulfide bonds,
characteristic of the SCR-containing complement receptors [1].
Thus, while these proteins are not identified by anti-MCR2, their
capacity to bind C3d and their decreased apparent molecular
weight under non-reducing conditions is consistent with SCR-
containing proteins.
We needed to exclude that nonspecific binding to C3d-Sepha-
rose could account for our results. Therefore, the following
studies compared proteins that bound specifically to C3d-Sepha-
rose with those that bound to BSA-Sepharose, a technique used
by others to validate specificity of binding to C3 columns [25—28].
Eluted from the BSA-Sepharose column were a number of faintly
visible protein bands from GEnC, along with a prominent 120
kDa protein (Fig. 6, lane 2, arrowhead), the identity of which is
unknown. In contrast, the 80, 200, and 300 kDa proteins were
strongly present by autoradiography after elution from the C3d-
Sepharose column (lane 1, arrows). In the experiments shown in
Figures 5 and 6, we observed a large molecular weight protein by
C3d affinity chromatography, which conceivably represents aggre-
gates of the C3 binding proteins. Therefore, the three C3d-
binding proteins of 80, 200, and 300 kDa do not appear to bind
Sepharose in a nonspecific fashion.
To establish the significance of GEnC C3 binding proteins,
studies were performed to evaluate whether these cells were
capable of binding C3b on sheep E. In these studies, GEnC bound
314.1 34.1 EC3b versus 58.7 7.3 E per high-powered field
(mean SEM, N = 9, P < 0.001). Therefore, the identified C3
receptors of GEnC bind particles bearing C3 fragments, such as
may occur in immune complexes.
RT-PCR and Northern analysis
Oligonucleotide primers for PCR were chosen from two highly
conserved regions in human and mouse CR2 that were separated
by 224 bases in both species with the rationale that these would
also be conserved in the rat. As shown by the arrow in Figure 7A,
a 224 bp PCR product was generated from rat GEnC cDNA (lane
1) and normal rat kidney cDNA (lane 3) using these primers.
These were identical in size to that generated in parallel from
mouse spleen cDNA (lane 4). PCR was also performed on rat and
mouse genomic DNA. By this approach, a 600 bp PCR product
was generated from mouse DNA (Fig. 7B, lane 2), consistent with
the known presence of an intron between SCRs 11 and 12 [71. The
same sized product was also generated from rat genomic DNA
(lane 1). Thus, the rat and mouse appear to have comparable
mRNA and genomic DNA for CR2 at SCRs 11 and 12.
The 224 bp rat GEC PCR product was purified by preparative
agarose gel electrophoresis, 32P labeled, and then used in North-
ern analyses. As shown in Figure 8, this CR2 probe hybridized to
2 and 5 kb mRNA bands from cultured GEnC (arrows, lane 1).
The 5 kb mRNA band was also present in RNA from rat kidney.
Therefore, cultured rat GEnC contain CR2 mRNA. CR2 mRNA
is also present in vivo in normal kidney.
Discussion
Here we show the presence of five apparently novel proteins on
cultured GEnC. Two proteins are reactive with antibodies raised
to recombinant mouse CR2. At least one of these proteins is
present in vivo as shown by our immunohistochemical data. The
other three proteins are C3d-binding proteins that are immuno-
chemically distinct from the proteins identified by anti-MCR2. We
also show that GEnC have mRNA with 224 nucleotides that have
similarity to that of mouse CR2. These 224 bases appear to be
contained in mRNA transcripts of 2 and 5 kb, as shown by our
Northern analysis data. The 5 kb CR2 mRNA is also present in
vivo.
The identity of the 120 and 150 kDa proteins reactive with
anti-MCR2 is confusing. We have shown a nearly identical
immunoprecipitation profile from rat neutrophils using anti-
MCR2, while rat erythrocytes do not have either protein [14].
These neutrophil proteins bound C3b-Sepharose to a minor
extent [141. This may reflect that the column contained C3bi, as an
inevitable contaminant of rat C3b preparation [18], to which CR2
can bind [29, 301. In ongoing studies, we have also shown that
mouse platelets contain large quantities of 125 and 150 kDa
proteins identified by anti-MCR2. These proteins bound to mouse
C3d-Sepharose [311. This background information supports that








Fig. 8. Northern analysis of GEnC and rat kidney RNA using the rat CR2
RT-PCR product. Following autoradiography, the membrane was stripped
and reprobed with a /3-actin eDNA. Both lanes were run on the same gel,
but have been spliced for this analysis.
the proteins identified by anti-MCR2 are relevant to the comple-
ment system. Based upon our data in other cells, the interaction of
these proteins with C3 fragments may be of such a low affinity that
we were unable to document C3d binding in these GEnC proteins.
The presence of 80 and 200 kDa C3d binding proteins in GEnC
is reproducible. The finding of a 300 kDa C3d binding protein is
also consistent, although its intensity varies. Our observations
cannot be attributable to nonspecific binding to Sepharose affinity
columns under low ionic strength conditions (0.05 M NaC1), as
shown by our experiments using BSA-Sepharose. We also conclu-
sively show that these proteins are unrelated to those identified by
anti-MCR2. Similar to the findings with anti-MCR2, a nearly
identical profile was seen in rat neutrophils using C3b affinity
chromatography, even down to the observation that the 300 kDa
product was variably present in different neutrophil isolations
[14]. Because we used a single line of GEnC, we can't attribute
this variation to genotypic differences, and may simply reflect
minor experimental variations from day-to-day. It is possible that
the 80 and 200 kDa C3d- and C3b-binding GEnC proteins we
have identified here are the same as the neutrophil proteins we
have termed C3bR-80 and C3bR-200, respectively [14]. In those
studies, we did not determine if the C3b-binding proteins also
bound C3d.
It is worth noting that human and mouse CR3 and CR4, which
are members of the integrin superfamily, are C3 binding proteins
[29]. While the molecular weights of 80 and 200 kDa could be
consistent with the /3 and a chains, respectively, of either CR3 or
CR4, these proteins are not rat CR3 or CR4 for the following
reasons. First, the C3d column did not contain any C3bi, to which
CR3 and CR4 specifically bind. Second, we performed C3d
affinity chromatography in the presence of EDTA, which elimi-
nates the divalent cation-dependent binding of CR3 and CR4 to
C3bi [29]. The fact that the GEnC proteins bound to C3d as well
as to C3b indicates that at least one binding site for these proteins
resides in the C3d portion of C3, as with human and mouse CR1
and CR2 [30, 32—34]. The C3 binding and apparent presence of
intrachain disulfide bonds are consistent with these C3d-binding
proteins containing the basic SCR repeating structure common to
mouse and human C3 binding proteins. Proof for this will require
cloning the cDNA for these proteins.
To identify mRNA for rat CR2, we chose a highly conserved
area in human and mouse CR2 to design primers for RT-PCR.
This was a successful approach, and illustrated that rat GEnC
contain mRNA with similarities to those encoding human and
mouse CR2. That this is relevant in vivo comes from the finding
that an identically sized RT-PCR product was generated from rat
kidney. By Northern blotting we confirmed the presence of CR2
mRNA in cultured GEnC and in the kidney in vivo. It is worth
noting that the CR2 PCR product was generated from SCRs 11—
12 of CR2, while the anti-MCR2 antibody used here is reactive
towards SCRs 1-10, so a direct link between the immunoprecipi-
tation and Northern analysis data cannot be made. It does seem
likely that the 2 and 5 kb CR2 mRNA transcripts are translated
into anti-MCR2 reactive proteins, but this also requires proof.
Until now, the only C3-binding cell type in the glomerulus was
believed to be the visceral glomerular epithelial cell. Observations
made twenty years ago placed C3 receptors on this cell in humans
[35], which later was identified as CR1 [36]. Kasinath et al
identified C3b and C3d receptors on cultured rat glomerular
epithelial cells [22], and in later studies, we identified a 200 kDa
C3b-binding protein on these cells [18]. Cultured GEnC can now
be added to the list as a glomerular cell type that has C3 receptors.
Largely through the work of Sacks and Daha, and their
colleagues, it is becoming increasingly apparent that intrinsic
glomerular cells are capable of synthesizing complement compo-
nents [37—42]. Although this has the potential to be injurious to
cells under certain conditions, it seems likely that complement
production by glomerular cells serves a useful purpose. Given that
the glomerulus is constantly exposed to immune complexes,
production of complement by intrinsic cells can facilitate dissolu-
tion of immune complexes [43]. To this end, cultured GEnC also
produce C3 (S. Adler, S.H. Sacks, unpublished observations).
Once C3b is deposited on immune complexes, either from fluid
phase or locally produced C3, and further cleaved to C3bi and
C3d by circulating factor I, a mechanism should exist for subse-
quent metabolism of these complexes. The presence of C3
receptors on GEnC provides one such mechanism for the removal
of potentially inflammatory immune complexes.
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